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Abstract: A mild and versatile method based on Cu-catalyzed [2+3] cycloaddition (Huisgen-Meldal-
Sharpless reaction) was developed to tether 3,3’-((4-(prop-2-yn-1-yloxy)phenyl)methylene)bis(4-
hydroxyquinolin-2(1H)-ones) with 4-azido-2-quinolones in good yields. This methodology allowed
attaching three quinolone molecules via a triazole linker with the proposed mechanism. The products
are interesting precursors for their anti-proliferative activity. Compound 8g was the most active one,
achieving IC50 = 1.2 ± 0.2 µM and 1.4 ± 0.2 µM against MCF-7 and Panc-1 cell lines, respectively.
Moreover, cell cycle analysis of cells MCF-7 treated with 8g showed cell cycle arrest at the G2/M
phase (supported by Caspase-3,8,9, Cytochrome C, BAX, and Bcl-2 studies). Additionally, significant
pro-apoptotic activity is indicated by annexin V-FITC staining.
Keywords: click; azido; quinolones; triazole; anti-proliferative; apoptosis
1. Introduction
One of the most common heterocycles in drug development is the quinolone (oxo-
quinoline) ring system [1,2]. Quinolone derivatives have been widely used in medicinal
chemistry due to their unique structure, which exhibits a variety of pharmacological
activities [3], especially antibacterial [4] and anti-cancer [5], with a promising role in
the improvement of anti-cancer drug resistance [6]. Many quinolone derivatives exhibit
excellent results in various operations, including growth inhibition via cell cycle arrest,
apoptosis, and angiogenesis inhibition (Compounds I, II, and III, Figure 1) [7–9].
Triazole derivatives have a wide range of biological activities [10]. Furthermore, some
drugs currently in clinical use are based on triazoles’ backbone, especially 1,2,3 triazole
moiety [11,12]. Combining the quinolone scaffold with the triazole moiety will result in
new leads with complementary activities and/or multiple pharmacological goals, and/or
one component will counterbalance the side effects caused by the other [13,14]. Click
chemistry is a simple method for assembling new molecular entities. The wide scope of
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CuAAC is firmly demonstrated by its use in different areas of life and material sciences
fields, including drug discovery and bioconjugation [15,16].
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Based on the preceding discussion and our efforts to produce quinoline derivatives 
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phenoxide linker. The newly synthesized compounds were tested for anti-proliferative 
efficacy against four different cancer cell lines. The most active ones were investigated 
further for their possible apoptotic activity utilizing extrinsic and intrinsic apoptotic indi-
cators. 
2. Results 
2.1. Chemistry Section 
Here, in our present work, we synthesized a new various classes of quinolones/tria-
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quinolinones 7a–d and 3,3′-((4-(prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxy-
quinolin-2(1H)-ones) 4a–c by a Cu-catalyzed [3+2] cycloaddition, as shown in Scheme 2. 
We initially examined the synthesis of novel terminal alkynes 4a–c via interaction between 
4-hydroxy-quinoline-2(1H)-ones 1a–c [20,21] and p-hydroxybenzaldehyde (2) (molar ratio 
2:1) in absolute ethanol catalyzed with triethyl amine under refluxing conditions to yield 
3,3′-((4-hydroxy-phenyl)methylene)bis(4-hydroxyquinolin-2(1H)-ones) 3a–c. In DMF, the 
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2. Results
2.1. Chemistry Section
Here, in our present work, we synthesized a new various classes of quinolones/triazoles
(Schemes 1 and 2) as 3,3’-((4-((1-(2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)methylene)bis(4-hydroxyquinolin-2(1H)-ones) 8a–l from 4-azido-2-quinolinones 7a–d
and 3,3’-((4-(prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxy-quinolin-2(1H)-ones) 4a–c
by a Cu-catalyzed [3+2] cycloaddition, as shown in Scheme 2. We initially examined the syn-
thesis of novel terminal alkynes 4a–c via interaction between 4-hydroxy-quinoline-2(1H)-ones
1a–c [20,21] and p-hydroxybenzaldehyde (2) (molar ratio 2:1) in absolute ethanol catalyzed
with triethyl amine under refluxing conditions to yield 3,3’-((4-hydroxy-phenyl)methylene)bis
(4-hydroxyquinolin-2(1H)-ones) 3a–c. In DMF, the resulting phenol compound interacts with
propargyl bromide to produce our terminal alkynes 4a–c in good yield.
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To confirm the structures of the obtained products 3,3’-(4-(prop-2-yn-1-yloxy)phenyl)
methylene)-bis(4-hydroxy-quinolin-2(1H)-ones) 4a–c, the elemental analysis declares that
the acquired molecular formula for 4a–c is generated from two molecules of compounds
1a–c and one molecule of aldehyde 5 with the elimination of H2O molecule or one molecule
of 3a–c and one molecule of propargyl bromide with HBr molecule elimination. We discuss
here the assignment of compound 4b, which was expected to be 3,3’-((4-(prop-2-yn-1-
yloxy)phenyl)methylene)bis-(4-hydroxy-6-methoxyquinolin-2(1H)-one) as an example for
the new terminal alkynes 4a–c (Figure 2).
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correlation with H-a and are assigned on chemical shift. Additionally, compound 4b has 
a tautomeric form 4b′ in which the two quinolinone rings are in the same direction. How-
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H-5 and H-5′ are not equivalent: that means, the two quinolinone rings are spectroscopi-
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scopically non-equivalent, some of their signals co-resonate because their rotation is hin-
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The 1 NMR spectrum showed a characteristic four broad singlet signals at δH = 13.39,
12.90, 12.19, and 12.08 ppm, integrating four D2O exchangeable protons assigned as OH-
4/4’, OH-4’/4, NH-1/1’, and NH-1’/1, respectively. Additionally, a singlet at δH = 6.14 ppm
(1H) corresponded to q-CH-(H-a), which further confirmed from 13C NMR with a char-
acteristic singlet at δC = 34.69 ppm (Table 1). The two methoxy groups with six protons
exhibit a singlet at δ = 3.77 ppm, which further confirmed from 13C NMR with a charac-
teristic singlet at δC = 55.41 ppm (C-6a, 6a’). Furthermore, the 1,4-disubstituted system was
observed for the phenyl ring as doublet–doublet at δH = 7.02 (d, J = 8.5 Hz; 2H, H-o) and δH
= 6.89 (d, J = 8.8 Hz; 2H, H-m), and both of them give 1H-1H-COSY correlation with each
other and HMBC correlation with H-a and H-o (Table 1). In its 13C NMR spectra, C-8/8’
also gives HMBC correlation with a 2H doublet at δH 7.26 ppm, assigned as H-6/6’; its
attached carbon appears at δC = 154.80 ppm, grounds as C-2,2’,4,4’. The 6H methyl singlet
at δH = 3.77 must be H-6a/6a’ and gives HSQC correlation to carbon at δC = 55.41 ppm. C-a
gives HMBC correlation to a 1H singlet at δH = 6.14, assigned as H-a; its attached carbon
appears at δC = 34.69 ppm. Additionally, the four lines between δC = 166–160 give HMBC
correlation with H-a and are assigned on chemical shift. Additionally, compound 4b has a
tautomeric form 4b’ in which the two quinolinone rings are in the same direction. How-
ever, from 1H NMR spectra, it is clear that the two OH groups, the two NH groups, and
H-5 and H-5’ are not equivalent: that means, the two quinolinone rings are spectroscop-
ically non-equivalent because their rotation is hindered, so that the compound does not
possess a σ-plane. The simplest rationale is that the tautomer populations of the two
quinolinones rings differ (tautomeric equilibration being relatively fast). Additionally,
the two quinolinone-NH, which were assigned as N-1/1’, give HSQC with a proton at
δH 12.08 ppm, and the other N-1’/1 give HSQC with a proton at δH 12.19 ppm, which
confirms that the two quinolone rings are not equivalent in comparison with the analogous
compound 6 prepared previously [22]. Although the two quinolinone rings are stated to be
spectroscopically non-equivalent, some of their signals co-resonate because their rotation
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is hindered, so that the compound does not possess a σ plane and must be assigned as 4b,
not 4b’.
Table 1. Spectrum data for compound 4b.
1H NMR 1H-1HCOSY Assignment
13.39 (bs; 1H) OH-4/4’
12.90 (bs; 1H) OH-4’/4
12.19 (bs; 1H) NH-1/1’
12.08 (bs; 1H) NH-1’/1
7.40 (d, J = 9.0; 2H) 7.26 H-8, 8’
7.40 (bs; 1H) H-5/5’
7.33 (bs; 1H) H-5’/5
7.26 (bd, J = 8.6; 2H) 7.40 H-7, 7’
7.02 (d, J = 8.5; 2H) 6.89 H-o
6.89 (d, J = 8.8; 2H) 7.02 H-m
6.14 (s; 1H) H-a
4.76 (d, J = 2.0; 2H) 3.55 H-b
3.77 (s; 6H) H-6a, 6a’
3.55 (bs; 1H) 4.76 H-d
15N NMR HSQC HMBC Assignment
144.2 12.08 7.40 N-1/1’
142.9 12.19 7.40 N-1’/1
13C NMR HSQC HMBC Assignment
165.76, 164.10 6.14 C-2, 2’
161.84, 160.91 6.14 C-4, 4’
155.31 7.02, 6.89, 4.76 C-p
154.80 7.40, 7.26, 3.77 C-6, 6’
131.52 7.40, 7.26 C-8a, 8a’
130.29 6.89, 6.14 C-i
127.29 7.02 7.02, 6.14 C-o
120.63 7.26 C-7, 7’
117.46 7.40 7.40 C-8, 8’
117.21, 116.70 7.40, 7.33 C-4a, 4a’
114.35 6.89 6.89, 6.89 C-m
111.74, 111.25 6.14 C-3, 3’
103.82 7.40, 7.33 C-5, 5’
79.43 4.76 C-c
78.00 3.55 3.55 C-d
55.41 3.77 C-6a, 6a’
55.34 4.76 C-b
34.69 6.14 7.02, 6.14 C-a
Secondly, 4-azido-2-quinolinones 7a–d reacted with 3,3’-((4-(prop-2-yn-1-yloxy)phenyl)
methylene)bis(4-hydroxyquinolin-2(1H)-ones) 4a–c in DMF as a solvent in molar ration
(1.2:1) and catalyzed by 10 mol% of CuI to give 3,3’-((4-((1-(2-oxo-1,2-dihydroquinolin-4-yl)-
1H-1,2,3-triazol-4-yl)methoxy)phenyl)methylene)-bis(4-hydroxyquinolin-2(1H)-one) 8a–l
in an excellent yields (Scheme 2).
Different spectral data (1H NMR, 13C NMR, 2D NMR, and 15N NMR; see Supple-
mentary Materials) addition to mass spectrometry, as well as elemental analyses, were
used to confirm the structures of all new compounds 8a–l. For example, compound 8f
was assigned as 3,3’-((4-((1-(6-methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)methylene)-bis(4-hydroxy-6-methoxyquinolin-2(1H)-one). It exhibited
a molecular formula of C40H32N6O8, representing a product from one molecule of 4b
and one molecule of 7b without elimination. Compound 8f was further confirmed by
mass spectrometry with m/z = 724 and elemental analysis (Figure 3), which confirm that
compound 8f is resulting from the reaction of compound 4b with 4-azido-6-methyl-2-
quinolinone 7b in molar ratio (1:1) without elimination.
Molecules 2021, 26, 6798 6 of 21




Scheme 2. Synthesis of the new target compounds 8a–l. 
Different spectral data (1H NMR, 13C NMR, 2D NMR, and 15N NMR; see Supplemen-
tary Materials) addition to mass spectrometry, as well as elemental analyses, were used 
to confirm the structures of all new compounds 8a–l. For example, compound 8f was as-
signed as 3,3′-((4-((1-(6-methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)methylene)-bis(4-hydroxy-6-methoxyquinolin-2(1H)-one). It exhib-
ited a molecular formula of C40H32N6O8, representing a product from one molecule of 4b 
and one molecule of 7b without elimination. Compound 8f was further confirmed by 
mass spectrometry with m/z = 724 and elemental analysis (Figure 3), which confirm that 
compound 8f is resulting from the reaction of compound 4b with 4-azido-6-methyl-2-
quinolinone 7b in molar ratio (1:1) without elimination. 
 
Figure 3. Structure of compound 8f. 
The 6-methyl-4-triazolo-2-quinolinone substructure (including the triazole ring) is
assigned by analogy with compound 8b. In both compounds, the two OH groups, the
two NH groups, and H-5 and H-5’ are not equivalent: the simplest rationale is that
the tautomer populations of the two quinolinone rings differ (tautomeric equilibration
being relatively fast). Consistent with this idea, N-1 and N-1’, C-2 and C-2’, C-3 and
C-3’, and C-4 and C-4’ are also non-equivalent in both samples; C-4a and C-4a’ are non-
equivalent in compound 4b, and C-8a and C-8a’ are non-equivalent in compound 8f
(Table 2, Exp. Section). The 1H-NMR spectrum of 8f showed five protons that appeared
as broad signals at δH 13.41, 12.91, 12.20, and 12.09 ppm for the quinolinone rings as
two hydroxyl groups OH-4/4’, OH-4’/4, quinolinone-N-1/1’,1” and quinolinone-N-1’/1,
respectively. These two protons were exactly assigned by analogy with 4b (Figure 2) and
2D NMR (Table 2). Additionally, there were five doublets at δH 7.47 (d, J = 8.3 Hz; H-7”),
7.40 (d, J = 9.2 Hz; 2H, H-8,8’), and 7.38 (d, J = 8.4 Hz; 2H, H-5/5’, 8”), in addition to a
1,4-disubstituted doublet-doublet at δH 7.05 (d, J = 8.2, Hz; 2H, H-o) and 7.01 (d, J = 8.2 Hz;
2H, H-m), and four singlets at δH 7.22, 6.81, 5.27, 3.82, and 2.29 ppm, which were assigned
as H-5”, H-a, H-3”, H-a, H-b, H-6b, 6b’, and H-6a”, respectively. The 13C NMR spectrum for
8f showed that four signals appeared at δC 165.85, 164.13, 161.84, and 160.84 ppm, assigned
as C-2,2’, C-4,4’, and C-2”,4”, respectively. Additionally, the signal at δC 60.85, which gives
HSQC correlation with the proton at δH 5.27, was assigned as C-b (-O-CH2), in addition to
two signals at 55.40 and 20.50 ppm, which was assigned for two methoxy groups (C-6b,
6b’) and methyl group (C-6a”), respectively. Furthermore, we see four types of nitrogen in
the 15N NMR spectrum; one of them appears at δN 247.4, which indicates an sp3 nitrogen;
it was assigned as N-e and gave HMBC correlation with a proton at δH 8.84 and 6.81 (H-d,
H-3”) but gives no HSQC correlation. The second nitrogen atom resonated at δN 151.6 ppm,
which assigned as N-1” and also gives HMBC correlation with a proton at δH 7.38 and
6.81 (H-5/5’, 8” and H-3”). The last two nitrogen at δN 144.2 and 142.8 ppm., which they
assigned as N-1’/1 and N-1/1’, and they give HSQC correlation with the attached protons
at δH 12.09 and 12.20, respectively.
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Table 2. Spectrum data for compound 8f.
1H NMR 1H-1HCOSY Assignment
13.41 (bs; 1H) OH-4/4’
12.91 (bs; 1H) OH-4’/4
12.20 (s; 2H) 6.81 NH-1/1’, 1”
12.09 (bs; 1H) NH-1’/1
8.84 (s; 1H) H-d
7.47 (d, J = 8.3; 1H) 7.38, 7.22 H-7”
7.40 (d, J = 9.2; 2H) 7.26 H-8, 8’
7.38 (d, J = 8.4; 2H) 7.47, 7.26, 2.29 H-5/5’, 8”
7.33 (m; 1H) 7.26 H-5’/5
7.26 (d, J = 8.1; 2H) 7.40, 7.38, 7.33 H-7, 7’
7.22 (s; 1H) 7.47, 2.29 H-5”
7.05 (d, J = 8.2; 2H) 7.01, 6.15 H-o
7.01 (d, J = 8.2; 2H) 7.05 H-m
6.81 (s; 1H) 12.20 H-3”
6.15 (bs; 1H) 7.05 H-a
5.27 (s; 2H) H-b
3.82 (s; 6H) H-6b, 6b’
2.29 (s; 3H) 7.40, 7.38, 7.26 H-6a”
13C NMR HSQC HMBC Assignment
165.85, 164.13 6.15 C-2, 2’
161.84 C-4, 4’
160.84 C-2”, 4”
156.06 7.05, 5.27 C-p
154.81 7.40, 3.82 C-6, 6’
143.42 8.84, 7.40, 7.22, 6.81,5.27 C-c
137.50 7.47, 7.22 C-8a”
133.15 7.47 7.47, 7.22 C-7”
131.73, 131.51 7.38, 7.26, 2.29 C-8a, 8a’
130.07 C-i
127.40 7.05 C-o, 6”
126.50 8.84 8.84,3 7.01, 5.27 C-d
123.15 7.22 7.47, 7.05, 2.29 C-5”
120.82 7.26 7.01 C-7, 7’
117.69 6.81 7.05, 6.813 C-3”
117.45 7.40 7.403 C-8, 8’
116.69 7.38, 7.33 C-4a, 4a’
115.89 7.38 C-8”
114.38 7.01 7.38, 6.81 C-m, 4a”
111.86, 110.18 6.15 C-3, 3’
103.81 7.38, 7.33 C-5, 5’
60.85 5.27 C-b
55.40 3.82 3.823 C-6b, 6b’
34.71 6.15 C-a
20.50 2.29 7.47, 7.22, 2.293 C-6a”
15N NMR HSQC HMBC Assignment
247.4 8.84, 6.81 N-e





2.2.1. Cell Viability Assay
A human mammary gland epithelial cell line was used in the cell viability assay
(MCF-10A). MCF-10A cells were incubated with compounds 8a–l for four days, and cell
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viability was determined using an MTT assay [23,24]. There were no cytotoxic effects in any
of the compounds tested, and most of the compounds tested had more than 84% viability
at 50 µM; Table 3 shows the results.





Anti-Proliferative Activity IC50 ± SEM (µM)
A-549 MCF-7 Panc-1 HT-29 Average(IC50)
8a 89 5.7 ± 0.4 5.3 ± 0.8 5.6 ± 0.6 5.7 ± 0.4 5.575
8b 87 7.6 ± 0.8 6.9 ± 0.8 7.6 ± 0.6 7.5 ± 0.4 7.400
8c 91 3.9 ± 0.5 3.2 ± 0.08 4.1 ± 0.2 4.2 ± 0.2 3.850
8d 89 12.9 ± 0.8 11.5 ± 1.1 11.6 ± 0.8 11.4 ± 1.2 11.850
8e 85 2.1 ± 0.2 1.5 ± 0.7 1.7 ± 0.1 2.2 ± 0.4 1.875
8f 87 2.9 ± 0.5 2.6 ± 0.8 3.1 ± 0.2 3.4 ± 0.2 3.000
8g 84 1.9 ± 0.2 1.2 ± 0.2 1.4 ± 0.2 1.8 ± 0.4 1.575
8h 90 10.7 ± 2.5 10.6 ± 2.9 10.8 ± 1.9 10.8 ± 1.6 10.725
8i 90 17.9 ± 0.3 17.8 ± 1.6 17.6 ± 1.5 17.9 ± 1.1 17.800
8j 81 22.5 ± 0.2 22.1 ± 0.1 22.4 ± 0.2 22.9 ± 0.6 22.474
8k 90 14.5 ± 2.6 13.6 ± 2.2 14.6 ± 2.9 14.8 ± 1.4 14.375
8l 96 25.3 ± 2.5 24.9 ± 1.8 24.5 ± 2.3 24.2 ± 1.4 24.725
Doxorubicin – 1.21 ± 0.80 0.90 ± 0.62 1.41 ± 0.58 1.01 ± 0.82 1.136
2.2.2. Cytotoxic Activity and Evaluation of IC50
Tested 8a–l compounds were assessed for their anti-proliferative activity against four
human cancer cell lines, including the pancreatic cancer cell line (Panc-1), breast cancer cell
line (MCF-7), colon cancer cell line (HT-29), and epithelial cancer cell line (A-549) using
propidium iodide fluorescence assay [25,26] and the reference doxorubicin. Results (IC50)
are illustrated in Table 3.
From the results, it is clear that the electronic effect of the substitution (R2 and/or R4)
on the phenyl groups of quinoline moieties is important for the antiproliferative activity.
Compounds 8c, 8e, 8f, and 8g (R2 and/or R4 = OCH3) were the most active compounds
against the tested four cell lines with average IC50 in the range of 1.575 to 3.850 µM.
Compound 8g (R1 = R3 = H, R2 = R4 = OCH3) showed the utmost antiproliferative activity
with average IC50 = 1.575 µM compared to the reference doxorubicin with average IC50
= 1.136 µM. Compounds 8e (R1 = R3 = R4 = H, R2 = OCH3, average IC50 = 1.875) and 8c
(R1 = R2 = R3 = H, R4 = OCH3, average IC50 = 3.850) showed higher IC50 (less potent)
than 8g. Replacement of OCH3 group either by H or CH3 resulted in a decrease in the
antiproliferative activity. For example, compounds 8a (R1 = R2 = R3 = H, R4 = H, average
IC50 = 5.575 µM) and 8b (R1 = R2 = R3 = H, R4 = CH3, average IC50 = 7.40 µM) showed a
1.5-fold and 2-fold decrease in activity relative to 8c, respectively.
Another significant factor influencing the efficacy of these compounds is the position
of substituent on the scaffold studied, which had a major impact on its cytotoxic activity.
Generally, triazoles 8a–c and 8e–g (R1 and/or R3 = H) showed superior anti-proliferative
activity compared to their N-methyl counterparts 8d, 8h, 8i, and 8j–l ((R1 and/or R3 = CH3),
Table 3. For example, the unsubstituted derivative 8a (R1 = R2 = R3 = R4 = H) showed an
average IC50 of 5.575 µM against the tested cell lines. Replacement of the NH group by
N-CH3, 8l (R1 = R3 = CH3, R2 = R4 = H, average IC50 = 24.725 µM) resulted in at least 4-fold
reduction of the average IC50 value. In addition, the average IC50 values of 8i–k (R1 and/or
R3 = CH3) were the lowest among the compounds tested, indicating the significance of the
NH group for anti-proliferative action.
2.2.3. Apoptosis Assay
To discover the pro-apoptotic capability of our target compounds, the utmost active
compounds 8e, 8f, and 8g were tested for their potential ability to induce apoptosis in a
MCF-7 breast cancer cell line.
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Activation of Proteolytic Caspases Cascade
Caspases play an important role in initiating and completing the apoptotic process [27].
Caspase 3 is an essential caspase that cleaves multiple proteins in cells, resulting in apop-
totic cell death [28]. The effects of compounds 8e, 8f, and 8g on Caspase 3 were investigated
and compared to that of doxorubicin. The findings revealed that when compared to control
cells, the studied compounds increased the level of active Caspase 3 by 5.5–7.5-fold and
that 8e, 8f, and 8g had unprecedented control over Caspase 3 protein level expression
(475.20 ± 4.27, and 365.60 ± 3.20, and 489.2 ± 4.13 pg/mL, respectively) compared to
doxorubicin (503.2 ± 4.22 pg/mL). Compared to control untreated cells, the most active
compound 8g showed a 7.45-fold increase in active Caspase 3 levels, Figure 4.




Figure 4. Effects of compounds 8e, 8f, and 8g, and doxorubicin on active Caspases 3, 8, 9, and Cyto-
chrome C in MCF-7 breast cancer cell line. 
Compounds 8e and 8g were also tested for their effects on Caspases 8 and 9. The 
results showed that compound 8g raises Caspase 8 and 9 levels by 8.94- and 15.03-fold, 
respectively. When compared to control cells, compound 8e showed a 7.58- and 13.86-fold 
increase in Caspase 8 and 9, respectively, indicating activation of both the intrinsic and 
extrinsic pathways, with the intrinsic pathway having a stronger effect since Caspase 9 
levels were higher [29]. 
Cytochrome C Assay 
The amount of cytochrome C in a cell plays an important role in caspase activation 
and the initiation of the intrinsic apoptosis pathway [29,30]. Table 4 shows the effects of 
testing triazole derivatives 8e and 8g as cytochrome C activators in the MCF-7 human 
breast cancer cell line. 8e and 8g resulted in around 11.90- and 12.76-fold higher levels of 
cytochrome C expression than untreated control cells. The findings add to the proof that 
apoptosis can be attributed to cytochrome C overexpression and activation of the intrinsic 
apoptotic pathway triggered by the tested compounds. 
Table 4. Effects of compounds 8e, 8f, 8g, and doxorubicin on active Caspases 3, 8, 9, and cytochrome C in MCF-7 breast 
cancer cell line. 
Compound No. 















8e 475.20 ± 4.27 7.23 1.29 7.58 12.89 13.86 0.548 11.90 
8f 365.60 ± 3.20 5.57 ND ND ND ND ND ND 
8g 489.20 ± 4.13 7.54 1.52 8.94 13.98 15.03 0.587 12.76 
Doxorubicin 503.20 ± 4.22 7.66 1.75 10.07 16.23 17.40 0.604 13.13 
Control 65.64 1 0.17 1 0.93 1 0.046 1 
ND: Not determined. 
Bax and Bcl-2 Levels Assay 
Using doxorubicin as a control, the most active caspase activators 8e and 8g were 
further investigated for their impact on Bax and Bcl-2 levels in the MCF-7 breast cancer 
cell line [31,32]. Table 5 shows that 8e and 8g elicited a significant increase in Bax levels as 
compared to doxorubicin. 8g demonstrated a comparable induction of Bax (264.90 pg/mL) 
relative to doxorubicin (276 pg/mL), 32-fold higher than the control untreated breast can-
cer cell, followed by compound 8e (247.65 pg/mL and 30-fold change). Finally, compound 
Figure 4. Effects of compounds 8e, 8f, and 8g, and doxorubicin on active Caspases 3, 8, 9, and
Cytochrome C in MCF-7 breast cancer cell line.
Co pounds 8e and 8g ere also tested for their effects on Caspases 8 and 9. The
results sho ed that co pound 8g raises Caspase 8 and 9 levels by 8.94- and 15.03-fold,
respectively. hen co pared to control cells, compound 8e showed a 7.58- and 13.86-fold
increase in Caspase 8 and 9, respectively, indicating activation of both the intrinsic and
extrinsic pathways, with the intrinsic pathway having a stronger effect since Caspase 9
levels were higher [29].
Cytochro e C Assay
The amount of cytochrome C in a cell plays an important role in caspase activation
and the initiation of the intrinsic apoptosis pathway [29,30]. Table 4 shows the effects of
testing triazole derivatives 8e and 8g as cytochrome C activators in the MCF-7 human
breast cancer cell line. 8e and 8g resulted in around 11.90- and 12.76-fold higher levels of
cytochrome C expression than untreated control cells. The findings add to the proof that
apoptosis can be attributed to cytochrome C overexpression and activation of the intrinsic
apoptotic pathway triggered by the tested compounds.





















8e 475.20 ± 4.27 7.23 1.29 7.58 12.89 13.86 0.548 11.90
8f 365.60 ± 3.20 5.57 ND ND ND ND ND ND
8g 489.20 ± 4.13 7.54 1.52 8.94 13.98 15.03 0.587 12.76
Doxorubicin 503.20 ± 4.22 7.66 1.75 10.07 16.23 17.40 0.604 13.13
Control 65.64 1 0.17 1 0.93 1 0.046 1
ND: Not determined.
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Bax and Bcl-2 Levels Assay
Using doxorubicin as a control, the most active caspase activators 8e and 8g were
further investigated for their impact on Bax and Bcl-2 levels in the MCF-7 breast cancer
cell line [31,32]. Table 5 shows that 8e and 8g elicited a significant increase in Bax levels as
compared to doxorubicin. 8g demonstrated a comparable induction of Bax (264.90 pg/mL)
relative to doxorubicin (276 pg/mL), 32-fold higher than the control untreated breast cancer
cell, followed by compound 8e (247.65 pg/mL and 30-fold change). Finally, compound 8g
reduced Bcl-2 protein levels in MCF-7 cells to 1.085 ng/mL, followed by compound 8e
(1.278 ng/mL) and doxorubicin (0.98 ng/mL).
Table 5. Bax and Bcl-2 levels for compounds 8e, 8g, and Doxorubicin in MCF-7 breast cancer cell line.
Compound No.
Bax Bcl-2
Conc (pg/mL) Fold Change Conc (ng/mL) Fold Reduction
8e 247.65 29.98 1.278 3.97
8g 264.90 32.07 1.085 4.68
Doxorubicin 276.19 33.42 0.983 5.17
Cont. 8.26 1 5.086 1.00
Flow Cytometric Cell Cycle Analysis
Following treatment with the most active compound 8g, a cell cycle analysis was
performed on the MCF-7 cancer cell line [33,34]. Figure 5 shows that the percentage of
MCF-7 cell line cells in the G0/G1 phase was 53.61% in control and 36.25% after treatment
with compound 8g, whereas the percentage of cells in the S phase was reduced with
compound 8g (27.15%) compared to the control (42.01%). Compared to the control, the
percentage of MCF-7 cell line in the G2/M process increased to 36.6% after treatment with
8g (4.38%). Furthermore, the percentage of apoptotic cells in the Pre-G1 process increased
from 1.63% in control untreated MCF-7 cells to 26.57% and 22.17% in cells treated with 8g
and doxorubicin, respectively (Figures 6 and 7). According to the findings, 8g primarily
displayed cell cycle arrest at the G2/M phases. Furthermore, the investigated compound
is anti-proliferative rather than cytotoxic, resulting in programmed cell death and cell
cycle arrest.
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3. Conclusions
A series of novel conjugated heterocycles containing three quinolinone moieties
could be synthesized straightforwardly. The propargylated core of the phenoxide linker
with two molecules of quinolinone could be equipped with another tethered molecule
by reacting with 4-azido-2-quinolones via a Meldal–Sharpless click reaction. The tar-
get products 3,3’-((4-(prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxy-quinolin-2(1H)-
ones) were obtained in good to very good yields and were characterized by different
spectroscopic and elemental methods including 1H NMR, 13C NMR, 2D NMR, MS, and
elemental microanalyses.
The antiproliferative activity of the new compounds was tested against a panel of
cancer cell lines. Compound 8g demonstrated the highest antiproliferative activity with an
average IC50 = 1.575 M compared to doxorubicin (IC50 = 1.136 M). The results show that
the electronic effect of the substitution, as well as its position on the scaffold studied, have
a significant impact on the activity of these compounds.
The most active compounds were further investigated for caspase, cytochrome C acti-
vation, Bax activation, and Bcl-2 downregulation compared to doxorubicin. Compounds 8e
and 8g increased the levels of active Caspase 3, 8, and 9, indicating that both the intrinsic
and extrinsic pathways were activated, with the intrinsic pathway having a stronger effect
due to higher Caspase 9 levels. Compound 8g exhibited cell cycle arrest at the G2/M phase
with a significant pro-apoptotic activity.
4. Experimental
4.1. Chemistry
Melting points were determined on Stuart electrothermal melting point apparatus
and were uncorrected. All reactions were monitored with thin-layer chromatography
(TLC) on Merck alumina-backed TLC plates and visualized under UV light. NMR spectra
were measured in DMSO-d6 on a Bruker AV-400 spectrometer (400 MHz for 1H, 100 MHz
for 13C, and 40.54 MHz for 15N), at the Chemistry Department, Florida Institute of Tech-
nology, 150 W University Blvd, Melbourne, FL 32901, USA, and Chemistry Department,
Faculty of Science, Cairo University, Cairo, Egypt. Chemical shifts are expressed in δ
(ppm) versus internal Tetramethylsilane (TMS) = 0 ppm for 1H and 13C, and external liquid
ammonia = 0 ppm for 15N. Coupling constants are stated in Hz. Correlations were estab-
lished using 1H-1H COSY, 1H-13C, and 1H-15N HSQC and HMBC experiments. Chemical
shifts (δ) are reported in parts per million (ppm) relative to Tetramethylsilane (TMS) as
an internal standard, and the coupling constants (J) are reported in Hertz (Hz). Splitting
patterns are denoted as follows: singlet (s), broad (b), doublet (d), multiplet (m), triplet (t),
quartet (q), broad of singlet (bs), doublet of doublets (dd), doublet of triplets (dt), triplet
of doublets (td), and doublet of a quartet (dq). Mass spectra were recorded on a Finnigan
Fab 70 eV at Al-Azhar University, Egypt. Elemental analyses were carried out on a Perkin
Elmer device at the Microanalytical Institute of Organic Chemistry, Karlsruhe Institute of
Technology, Karlsruhe, Germany.
4.1.1. Starting Materials
4-Hydroxy-quinoline-2(1H)-ones 1a–c [20,21], 3,3’-((4-hydroxy-phenyl)methylene)
bis(4-hydroxyquinolin-2(1H)-ones) 3a–c [22], 4-(prop-2-yn-1-yloxy)benzaldehyde 5 [35],
and 4-azido-2-quinolinones 7a–d [36] were synthesized according to the literature.
4-hydroxybenzaldehyde (5) and propargyl bromide (Aldrich) were used as received.
4.1.2. General Procedure for the Synthesis of Compounds 4a–c
Method A: A mixture of 4-hydroxy-2-quinolinones 1a–c (2 mmol), p-hydroxy-
benzaldehyde (2) (1 mmol), and 0.5 mL of Et3N in 20 mL absolute ethanol was refluxed for
6 h. The resulting white precipitate was left to cool and then poured into ice-cold water
to give 3a–c. The precipitate collected by filtration was dried well and then reacted with
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propargyl bromide in DMF in a molar ratio (1:2), and the reaction mixture was monitored
by TLC and then poured into about 200 g ice to give 4a–c, which was collected by filtration.
Method B: A mixture of 4-hydroxy-2-quinolinones 1a–c (2 mmol), 4-(prop-2-yn-1-
yloxy)benzaldehyde (5) (1 mmol), and 0.5 mL of Et3N in 20 mL absolute ethanol was
refluxed for 4h. The resulting white precipitate was left to cool and then filtered off to give
4a–c in excellent yields.
3,3’-((4-(Prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxyquinolin-2(1H)-one) 4a. Colorless
powder (85%), m.p. 296–98 ◦C; 1H NMR (DMSO-d6): δH = 13.12 (bs; 1H, OH-4/4’), 12.67
(bs; 1H, OH-4’/4), 12.24 (bs; 1H, NH-1/1’), 12.21 (bs; 1H, NH-1’/1), 7.98 (bs; 1H, H-5/5’),
7.95 (bd, J = 6.6 Hz; 1H, H-5’/5), 7.61 (dd, J = 7.6, 7.6 Hz; 2H, H-7, 7’), 7.45 (d, J = 8.2 Hz;
2H, H-8, 8’), 7.30 (bs; 2H, H-6, 6’), 7.03 (d, J = 8.5 Hz; 2H, H-o), 6.88 (d, J = 8.7 Hz; 2H, H-m),
6.14 (s; 1H, H-a), 4.76 (d, J = 1.8 Hz; 2H, H-b), 3.55 ppm (bs; 1H, H-d), 13C NMR (DMSO-d6):
δC = 165.90 (C-2/2’), 163.40 (C-2’/2), 161.00 (C-4, 4’), 155.35 (C-p), 137.00 (C-8a, 8a’), 131.10
(C-7, 7’), 130.16 (C-i), 127.31 (C-o), 123.15 (C-5, 5’), 122.52 (C-6, 6’), 115.87 (C-8, 8’), 114.36
(C-m), 110.80 (C-4a, 4a’), 79.41 (C-c), 78.01 (C-d), 55.34 (C-b), 34.50 ppm (C-a), 15N NMR
(DMSO-d6): δN = 144.8 ppm (N-1, 1’). Anal. Calcd for C28H20N2O5: C, 72.41; H, 4.34; N,
6.03; Found: C, 72.59; H, 4.28; N, 6.18.
3,3’-((4-(Prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxy-6-methoxy-quinolin-2(1H)-one) 4b.
Colorless powder (90%), m.p. 283–85 ◦C; NMR (DMSO-d6) (Table 1). Anal. Calcd for
C30H24N2O7: C, 68.70; H, 4.61; N, 5.34; Found: C, 68.63; H, 4.55; N, 5.49.
3,3’-((4-(Prop-2-yn-1-yloxy)phenyl)methylene)bis(4-hydroxy-1-methylquinolin-2(1H)-one) 4c. Col-
orless powder (78%), m.p. 280–82 ◦C; 1H NMR (DMSO-d6): δH = 12.86 (bs, 1H; OH-4/4’),
12.52 (bs, 1H; OH-4’/4), 8.05 (bs, 2H; H-5, 5’), 7.71 (ddd, J = 7.3, 7.3, 0.9 Hz, 2H; H-7, 7’),
7.66 (d, J = 8.3 Hz, 2H; H-8, 8’), 7.37 (dd, J = 7.3, 7.2 Hz, 2H; H-6, 6’), 6.98 (d, J = 8.6 Hz, 2H;
H-o), 6.85 (d, J = 8.8 Hz, 2H; H-m), 6.23 (s, 1H; H-a), 4.75 (d, J = 2.2 Hz, 2H; H-b), 3.72 (bs,
6H; H-1a, 1a’), 3.56 (t, J = 2.2 Hz, 1H; H-d), 13C NMR (DMSO-d6): δC = 164.75 (b; C-2, 2’),
160.58 (b; C-4, 4’), 155.32 (C-p), 138.10 (C-8a, 8a’), 131.54 (C-7, 7’), 130.12 (C-i), 127.28 (C-o),
123.60 (C-5, 5’), 122.70 (C-6, 6’), 116.90 (C-4a, 4a’), 115.29 (C-8, 8’), 114.35 (C-m), 110.12 (b;
C-3, 3’), 79.42 (C-c), 78.02 (C-d), 55.31 (C-b), 35.98 (C-a), 30.12 ppm (b; C-1a, 1a’), 15N NMR
(DMSO-d6): δN = 138.7 ppm (N-1, 1’). Anal. Calcd for C30H24N2O5: C, 73.16; H, 4.91; N,
5.69; Found: C, 73.25; H, 4.81; N, 5.55.
4.1.3. General Procedure for the Synthesis of Compounds 8a–l
A mixture of terminal alkynes 4a–c (1.1 mmol) in 20 mL dimethylformamide (DMF)
and CuI (10 mmol%) was stirred for 10 min at room temperature. Then, 4-azido compounds
7a–d (1.0 mmol) were added to the mixture. The reaction mixture was allowed to stir at
50 ◦C for 24 h, and TLC was used to monitor the reaction. After completion, the mixture
was diluted with 50 mL H2O. The precipitate was filtered off to give 8a–l in excellent yields.
3,3’-((4-((1-(2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-methylene)bis
(4-hydroxyquinolin-2(1H)-one) 8a. Colorless powder, (75%), m.p. 280–82 ◦C; 1H NMR
(DMSO-d6): δH = 13.18 (bs; 1H, OH-4/4’), 12.69 (bs; 1H, OH-4’/4), 12.29 (bs; 3H, NH-1, 1’,
1”), 8.86 (s; 1H, H-d), 7.96 (m; 2H, H-5, 5’), 7.63 (bd; 3H, H-7, 7’, 7”), 7.46 (bs; 4H, H-5”, 8, 8’,
8”), 7.26 (m; 2H, H-6, 6’), 7.24 (dd, J = 7.4, 7.4 Hz; 1H, H-6”), 7.05 (m; 2H, H-o), 6.86 (m; 2H,
H-m), 6.16 (s; 1H, H-a), 5.27 ppm (s; 2H, H-b), 13C NMR (DMSO-d6): δC = 161.13, 160.77
(C-2, 2’, 2”, 4, 4’, 4”), 155.89 (C-p), 143.41, 143.25 (C-c), 139.18, 136.82 (C-8a, 8a’, 8a”), 131.61
(C-7, 7’, 7”), 130.83 (C-i), 127.22 (C-o), 123.74 (C-5”), 122.89 (C-5,5’), 122.34 (C-6, 6’, 6”),
117.48 (C-m), 116.37 (C-3, 3’, 3”), 115.69 (C-8, 8’, 8”), 114.22 (C-4a, 4a’, 4a”), 60.63 (C-b),
35.10 ppm (C-a), 15N NMR (DMSO-d6): δN = 247.50 (N-e or g), 152.50 (N-1”), 144.90 ppm
(N-1,1’). EI-MS (m/z, %): 650 (M+, 60). Anal. Calcd for C37H26N6O6: C, 68.30; H, 4.03; N,
12.92. Found: C, 68.44; H, 3.98; N, 13.02.
3,3’-((4-((1-(6-Methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxyquinolin-2(1H)-one) 8b. Colorless powder, (80%), m.p. 230–32 ◦C;
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1H NMR (DMSO-d6): δH = 13.17 (bs, 1H; OH-4/4’), 12.68 (bs, 1H; OH-4’/4), 12.20 (bs, 3H;
NH-1, 1’, 1”), 8.83 (s, 1H; H-d), 7.96 (m, 2H; H-5, 5’), 7.60 (t, J = 7.3, 2H; H-7, 7’), 7.46 (t,
J = 6.6, 3H; H-8, 8’, 7”), 7.38 (d, J = 8.4, 1H; H-8”), 7.30 (b, 2H; H-6, 6’), 7.22 (s, 1H; H-5”),
7.06 (d, J = 8.3, 2H; H-o), 7.01 (d, J = 8.4, 2H; H-m), 6.80 (s, 1H; H-3”), 6.16 (s, 1H; H-a), 5.26
(s, 2H; H-b), 2.28 ppm (s, 3H; H-6a”), 13C NMR (DMSO-d6): δC = 160.84 (C-2, 2’, 2”, 4, 4’,
4”), 156.09 (C-p), 143.42, 143.35 (C-c, 4”), 137.50 (C-8a”), 137.01 (C-8a, 8a’), 133.14 (C-7”),
131.73 (C-7, 7’), 131.09 (C-i), 127.43 (C-6”), 126.50 (C-d), 123.15 (C-5, 5’, 5”), 122.49 (C-6, 6’),
117.70 (C-3, 3’, 3”), 115.88 (C-8, 8’, 8”), 114.38 (C-o, m, 4a, 4a’, 4a”), 60.85 (C-b), 34.51 (C-a),
20.50 ppm (C-6a”), 15N NMR (DMSO-d6): δN = 247.2 (N-e), 151.8 (N-1”), 144.96 ppm (N-1,
1’), N-f, g n/o. EI-MS (m/z, %): 664 (M+, 28). Anal. Calcd for C38H28N6O6: C, 68.67; H,
4.25; N, 12.64. Found: C, 68.55; H, 4.33; N, 12.71.
3,3’-((4-((1-(6-Methoxy-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxyquinolin-2(1H)-one) 8c. Colorless powder, (82%), m.p. 255–57 ◦C;
1H NMR (DMSO-d6): δH = 13.17 (bs, 1H; OH-4/4’), 12.68 (bs, 1H; OH-4’/4), 12.19 (bs, 3H;
NH-1, 1’, 1”), 8.88 (s, 1H; H-d), 7.96 (m, 2H; H-5, 5’), 7.61 (m, 2H; H-7, 7’), 7.43 (bd, J = 9.0,
3H; H-8, 8’, 8”), 7.32 (bd, J = 8.3, 3H; H-6, 6’, 7”), 7.03 (bd, J = 9.7, 4H; H-o,m), 6.92 (bs, 1H;
H-5”), 6.85 (s, 1H; H-3”), 6.15 (bs, 1H; H-a), 5.27 (s, 2H; H-b), 3.67 ppm (s, 3H; H-6b”), 13C
NMR(DMSO-d6): δC = 166.40 (b), 164.85 (b; C-2, 2’), 161.38 (b; C-4, 4’), 160.54 (C-2”), 156.09
(C-p), 154.50 (C-6”), 143.50 (C-c), 143.10 (C-4”), 136.98 (C-8a, 8a’), 134.07 (C-8a”), 131.08
(C-7, 7’), 130.01 (b; C-i), 127.43 (C-o), 126.41 (C-d), 123.14 (C-5, 5’), 122.53 (C-6, 6’), 121.03
(C-7”), 117.95 (C-3”), 117.43 (C-8”), 115.88 (C-8, 8’), 114.84 (C-4a”), 114.38 (C-m), 111.38
(b; C-4a, 4a’), 110.15 (b; C-3), 105.51 (C-5”), 60.84 (C-b), 55.35 (C-6b”), 34.51 ppm (b; C-a),
15NNMR (DMSO-d6): δN = 248.1 (N-e), 151.0 (N-1”), 144.6 ppm (N-1, 1’), N-f, g n/o. EI-MS
(m/z, %): 680 (M+, 27). Anal. Calcd for C38H28N6O7: C, 67.05; H, 4.15; N, 12.35. Found: C,
66.97; H, 4.01; N, 12.43.
3,3’-((4-((1-(1-Methly-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxyquinolin-2(1H)-one) 8d. Colorless powder, (70%), m.p. 259–61 ◦C;
1H NMR (DMSO-d6): δH = 13.18 (bs, 1H; OH-4/4’), 12.68 (bs, 1H; OH-4’/4), 12.25 (bs, 2H;
NH-1, 1’), 8.84 (s, 1H; H-d), 7.96 (m, 2H; H-5, 5’), 7.75 (t, J = 7.2, 1H; H-7”), 7.70 (d, J = 8.2,
1H; H-8”), 7.61 (m, 2H; H-7, 7’), 7.44 (m, 3H; H-8, 8’, 5”), 7.32 (m, 3H; H-6, 6’, 6”), 7.04 (m,
4H; H-o,m), 6.89 (s, 1H; H-3”), 6.16 (bs, 1H; H-a), 5.27 (s, 2H; H-b), 3.71 ppm (s, 3H; H-1a”),
13C NMR (DMSO-d6): δC = 161.27 (b; C-4, 4’), 160.29 (C-2”), 156.14 (C-p), 143.46 (C-c),
142.62 (C-4”), 140.10 (C-8a”), 136.98 (b; C-8a, 8a’), 132.27 (C-7”), 131.08 (C-7, 7’), 129.97 (b;
C-i), 127.50 (C-o), 126.72 (C-d), 124.45 (C-5”), 123.11 (C-5, 5’), 122.71 (C-6, 6’, 6”), 117.18
(C-3”), 115.86 (C-8, 8’), 115.52 (C-8”), 114.43 (C-m), 114.84 (C-4a”), 60.87 (C-b), 34.60 (b;
C-a), 29.55 ppm (C-1a”). C-2, 2’, 3, 3’, 4a, 4a’ n/o; 15N NMR (DMSO-d6): δN = 246.7 (N-e),
147.1 (N-1”), 144.7 ppm (N-1, 1’), N-f, g n/o. EI-MS (m/z, %): 664 (M+, 28). Anal. Calcd for
C38H28N6O6: C, 68.67; H, 4.25; N, 12.64. Found: C, 68.58; H, 4.19; N, 12.77.
3,3’-((4-((1-(2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-methylene)bis
(4-hydroxy-6-methoxyquinolin-2(1H)-one) 8e. Colorless powder, (77%), m.p. 269–71 ◦C; 1H
NMR (DMSO-d6): δH = 13.41 (bs, 1H; OH-4/4’), 12.90 (bs, 1H; OH-4’/4), 12.27 (s, 1H;
NH-1”), 12.20 (bs, 1H; NH-1/1’), 12.09 (bs, 1H; NH-1’/1), 8.85 (s, 1H; H-d), 7.64 (dd, J = 7.5,
7.5, 1H; H-7”), 7.47 (d, J = 8.0, 1H; H-8”), 7.45 (d, J = 7.8, 1H; H-5”), 7.40 (m, 3H; H-8, 8’,
5/5’), 7.33 (m, 1H; H-5’/5), 7.25 (d, J = 7.3, 2H; H-7, 7’), 7.23 (m, 1H; H-6”), 7.03 (m, 4H;
H-o,m), 6.85 (s, 1H; H-3”), 6.15 (s, 1H; H-a), 5.26 (s, 2H; H-b), 3.82 ppm (s, 6H; H-6b, 6b’),
13C NMR(DMSO-d6): δC = 164.13 (b; C-2,2’), 161.86 (b; C-4,4’), 160.99 (C-2”), 156.09 (C-p),
154.82 (C-6,6’), 143.64 (C-c), 143.42 (C-4”), 139.41 (C-8a”), 131.85 (C-7”), 131.51 (b; C-8a, 8a’),
130.08 (b; C-i), 127.40 (C-o), 126.50 (C-d), 123.98 (C-5”), 122.58 (C-6”), 120.83 (C-7,7’), 117.69
(C-8,8’), 117.47 (C-3”), 116.71 (b; C-4a, 4a’), 115.92 (C-8”), 114.45 (C-m,4a”), 111.77 (b; C-3,
3’), 103.82 (C-5, 5’), 60.87 (C-b), 55.41 (C-6b, 6b’), 34.72 ppm (C-a), 15N NMR (DMSO-d6):
δN = 247.5 (N-e), 152.2 (N-1”), 144.1 (N-1’/1), 143.0 ppm (N-1/1‘), N-f, g n/o. EI-MS (m/z,
%): 710 (M+, 28). Anal. Calcd for C39H30N6O8: C, 65.91; H, 4.25; N, 11.83. Found: C, 66.09;
H, 4.33; N, 11.79.
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3,3’-((4-((1-(6-Methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-6-methoxyquinolin-2(1H)-one) 8f. Colorless powder, (82%), m.p.
264–66 ◦C; NMR (DMSO-d6) (Table 2). EI-MS (m/z, %): 724 (M+, 22). Anal. Calcd for
C40H32N6O8: C, 66.29; H, 4.45; N, 11.60. Found: C, 66.33; H, 4.42; N, 11.57.
3,3’-((4-((1-(6-Methoxy-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-6-methoxyquinolin-2(1H)-one) 8g. Colorless powder, (83%), m.p.
270–72 ◦C; 1H NMR (DMSO-d6): δH = 13.41 (bs, 1H; OH-4/4’), 12.91 (bs, 1H; OH-4’/4),
12.21 (bs, 2H; NH-1/1’, 1”), 12.11 (bs, 1H; NH-1’/1), 8.89 (s, 1H; H-d), 7.42 (m, 4H; H-5/5’, 8,
8’, 8”), 7.33 (m, 2H; H-5’/5, 7”), 7.26 (m, 2H; H-7, 7’), 7.03 (m, 4H; H-o,m), 6.92 (s, 1H; H-5”),
6.85 (s, 1H; H-3”), 6.15 (bs, 1H; H-a), 5.27 (s, 2H; H-b), 3.82 (s, 6H; H-6b, 6b’), 3.67 ppm
(s, 3H; H-6b”), 13C NMR (DMSO-d6): δC = 165.84 (b), 164.16 (b; C-2, 2’), 161.83 (b), 160.93
(b; C-4, 4’), 160.52 (C-2”), 156.05 (C-p), 154.81 (C-6, 6’), 154.50 (C-6”), 143.48 (C-c), 143.09
(C-4”), 134.07 (C-8a”), 131.58 (b; C-8a, 8a’), 130.09 (b; C-i), 127.40 (C-o), 126.41 (C-d), 121.04
(C-7”), 120.84 (C-7, 7’), 117.95 (C-3”), 117.44, 116.69 (b; C-8, 8’, 8”), 114.83 (C-4a”), 114.38
(C-m), 111.75 (b; C-3, 3’), 110.23 (b; C-4a, 4a’), 105.50 (C-5”), 103.80 (C-5, 5’), 60.84 (C-b),
55.35, 55.11 (b; C-6b, 6b’, 6b”), 34.71 ppm (b; C-a), 15N NMR (DMSO-d6): δN = 247.3 (N-e),
151.0 (N-1”), 144.4 (N-1’/1), 143.0 ppm (N-1/1‘), N-f, g n/o. EI-MS (m/z, %): 740 (M+, 26).
Anal. Calcd for C40H32N6O9: C, 64.86; H, 4.35; N, 11.35. Found: C, 64.80; H, 4.44; N, 11.21.
3,3’-((4-((1-(1-Methly-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-6-methoxyquinolin-2(1H)-one) 8h. Colorless powder, (69%), m.p.
260–62 ◦C; 1H NMR (DMSO-d6): δH = 13.41 (bs, 1H; OH-4/4’), 12.89 (bs, 1H; OH-4’/4),
12.19 (b, 1H; NH-1/1’), 12.08 (b, 1H; NH-1’/1), 8.84 (s, 1H; H-d), 7.77 (dd, J = 7.5, 7.5, 1H;
H-7”), 7.71 (d, J = 8.3, 1H; H-8”), 7.41 (m, 4H; H-5”,8,8’,5/5’), 7.33 (m, 2H; H-6”,5’/5), 7.26
(bd, J = 6.8, 2H; H-7, 7’), 7.02 (m, 4H; H-o,m), 6.94 (s, 1H; H-3”), 6.15 (s, 1H; H-a), 5.27 (s,
2H; H-b), 3.82 (bs, 6H; H-6b, 6b’), 3.72 ppm (s, 3H; H-1a”), 13C NMR (DMSO-d6): δC =
164.14 (C-2,2’), 162.29 (C-4, 4’), 160.29 (C-2”), 156.09 (C-p), 154.78 (C-6, 6’), 143.42 (C-c),
142.62 (C-4”), 140.10 (C-8a”), 132.26 (C-7”), 131.42 (C-8a, 8a’), 130.09 (C-i), 127.39 (C-o),
126.70 (C-d), 124.44 (C-5”), 122.71 (C-6”), 120.83 (C-7, 7’), 117.47 (C-8, 8’), 117.18 (C-3”, 4a,
4a’), 115.52 (C-8”), 114.41 (C-m, 4a”), 103.82 (C-5, 5’), 60.89 (C-b), 55.41 (C-6b, 6b’), 34.64
(C-a), 29.56 ppm (C-1a”). C-3, 3’ n/o, 15N NMR (DMSO-d6): δN = 246.5 (N-e), 147.1 (N-1”),
144.2 ppm (N-1, 1’), N-f, g n/o. EI-MS (m/z, %): 724 (M+, 37). Anal. Calcd for C40H32N6O8:
C, 66.29; H, 4.45; N, 11.60. Found: C, 66.22; H, 4.33; N, 11.75.
3,3’-((4-((1-(2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-methylene)bis
(4-hydroxy-1-methylquinolin-2(1H)-one) 8i. Colorless powder, (72%), m.p. 265–67 ◦C; 1H
NMR (DMSO-d6): δH = 12.87 (bs, 1H; OH-4/4’), 12.54 (bs, 1H; OH-4’/4), 12.27 (bs, 1H;
NH-1”), 8.85 (s, 1H; H-d), 8.07 (bs, 2H; H-5, 5’), 7.71 (m, 2H; H-7, 7’), 7.64 (m, 3H; H-8,
8’, 7”), 7.46 (m, 2H; H-5”, 8”), 7.39 (b, 2H; H-6, 6’), 7.23 (t, J = 7.6, 1H; H-6”), 7.01 (m, 4H;
H-o,m), 6.84 (s, 1H; H-3”), 6.25 (bs, 1H; H-a), 5.25 (s, 2H; H-b), 3.73 ppm (bs, 6H; H-1a, 1a’),
13C NMR (DMSO-d6): δC = 165.77 (b), 164.20 (b; C-2, 2’), 160.97 (C-4, 4’, 2”), 156.11 (C-p),
143.62 (C-4”), 143.40 (C-c), 139.41 (C-8a”), 138.14 (C-8a, 8a’), 131.84 (C-7, 7’, 7”), 131.58
(C-i), 127.41 (C-o), 126.51 (C-d), 123.97 (C-5”), 123.61 (C-5, 5’), 122.74 (C-6, 6’), 122.56 (C-6”),
117.69 (C-3”), 116.94 (b; C-4a, 4a’), 115.90 (C-8”), 115.34 (C-8, 8’), 114.44 (C-m), 110.92 (b;
C-3, 3’), 60.84 (C-b), 36.00 (C-a), 30.18 ppm (C-1a, 1a’), 15N NMR (DMSO-d6): δN = 247.5
(N-e), 152.2 ppm (N-1”), N-1, 1’, f, g n/o. EI-MS (m/z, %): 678 (M+, 35). Anal. Calcd for
C39H30N6O6: C, 69.02; H, 4.46; N, 12.38. Found: C, 68.99; H, 4.35; N, 12.55.
3,3’-((4-((1-(6-Methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-1-methylquinolin-2(1H)-one) 8j. Colorless powder, (77%), m.p.
222–24 ◦C; 1H NMR (DMSO-d6): δH = 12.92 (bs, 1H; OH-4/4’), 12.50 (bs, 1H; OH-4’/4),
12.22 (bs, 1H; NH-1”), 8.83 (s, 1H; H-d), 8.03 (b, 2H; H-5, 5’), 7.65 (m, 4H; H-7, 7’, 8, 8’),
7.42 (bd, J = 8.6 Hz, 1H; H-7”), 7.35 (d, J = 8.2 Hz, 3H; H-6, 6’, 8”), 7.20 (s, 1H; H-5”), 6.99
(m, 4H; H-o, m), 6.80 (s, 1H; H-3”), 6.23 (bs, 1H; H-a), 5.25 (s, 2H; H-b), 3.71 (bs, 6H; H-1a,
1a’), 2.25 ppm (s, 3H; H-6a”), 13C NMR (DMSO-d6): δC = 165.58 (b), 164.36 (b; C-2, 2’, 2”),
160.84 (C-4, 4’, 4”), 158.06 (C-p), 143.39 (C-c), 138.08 (C-8a, 8a’), 137.50 (C-8a”), 133.08 (C-7”),
Molecules 2021, 26, 6798 16 of 21
131.68, 131.47 (C-7, 7’), 129.91 (b; C-i), 127.39 (C-o, 6”), 126.48 (C-d), 123.57 (C-5, 5’), 123.12
(C-5”), 122.64 (C-6, 6’), 117.67 (C-3”), 116.90 (b; C-4a, 4a’), 115.87 (C-8”), 115.20 (C-8, 8’),
114.36, 114.32 (C-m, 4a”), 110.49 (b), 109.92 (b; C-3, 3’), 60.81 (C-b), 36.00 (C-a), 30.07 (b;
C-1a, 1a’), 20.47 ppm (C-6a”), 15N NMR (DMSO-d6): δN = 247.9 (N-e), 151.9 ppm (N-1”),
N-1, 1’, f, g n/o. EI-MS (m/z, %): 692 (M+, 10). Anal. Calcd for C40H32N6O6: C, 69.35; H,
4.66; N, 12.13. Found: C, 69.44; H, 4.55; N, 12.22.
3,3’-((4-((1-(6-Methoxy-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-tri-azol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-1-methylquinolin-2(1H)-one)) 8k. Colorless powder, (71%), m.p.
235–37 ◦C; 1H NMR (DMSO-d6): δH = 12.84 (bs, 1H; OH-4/4’) 12.55 (bs, 1H; OH-4’/4),
12.44 (bs, 1H; NH-1”), 8.86 (s, 1H; H-d), 8.02 (bs, 2H; H-5, 5’), 8.87(m, 4H; H-7, 7’, 8, 8’), 7.85
(d, 1H; H-7”), 7.39 (d, 3H; H-6, 6’, 8”), 7.31 (s, 1H; H-5”), 6.92 (m, 4H; H-o, m), 6.65 (s, 1H;
H-3”), 6.23 (bs, 1H; H-a), 5.42 (s, 2H; H-b), 3.09 (bs, 6H; H-1a, 1a’), 2.49 ppm (s, 3H; H-6a”),
13C NMR (DMSO-d6): δC = 160.27 (C-4, 4’, 4”), 156.12 (C-p), 143.52 (C-c), 138.08 (C-8a, 8a’),
132.20 (C-8a”), 131.51 (C-7”), 130.43, 130.07 (C-7, 7’), 127.44 (b; C-i), 126.73 (C-o, 6”), 124.45
(C-5, 5’), 123.60 (C-5”), 122.68 (C-6, 6’), 117.11 (C-3”), 117.51 (b; C-4a, 4a’), 115.42 (C-8”),
115.23 (C-8, 8’), 114.36 (C-m), 60.81 (C-b), 36.05 (C-a), 30.09 ppm (b; C-1a, 1a’). EI-MS (m/z,
%): 708 (M+, 21). Anal. Calcd for C40H32N6O7: C, 67.79; H, 4.55; N, 11.86. Found: C, 67.88;
H, 4.66; N, 12.01.
3,3’-((4-((1-(1-Methyl-2-oxo-1,2-dihydroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)
methylene)bis(4-hydroxy-1-methylquinolin-2(1H)-one) 8l. Colorless powder, (66%), m.p.
220–22 ◦C; 1H NMR (DMSO-d6): δH = 12.15 (bs, 2H; OH-4/4’, OH-4’/4), 12.21 (bs, 1H;
NH-1”), 8.86 (s, 1H; H-d), 8.02 (bs, 2H; H-5, 5’), 7.61 (m, 4H; H-7, 7’, 8, 8’), 7.39 (d, 1H; H-7”),
7.31 (d, 3H; H-6, 6’, 8”), 7.28 (s, 1H; H-5”), 6.98 (m, 4H; H-o, m), 6.90 (s, 1H; H-3”), 6.23
(bs, 1H; H-a), 5.24 (s, 2H; H-b), 2.31 (bs, 6H; H-1a, 1a’), 2.29 ppm (s, 3H; H-6a”), 13C NMR
(DMSO-d6): δC = 160.65 (C-4, 4’, 4”), 156.16 (C-p), 143.17 (C-c), 138.16 (C-8a, 8a’), 134.16
(C-8a”), 131.58 (C-7”), 131.58, 130.07 (C-7, 7’), 127.51 (b; C-i), 126.50 (C-o, 6”), 123.68 (C-5,
5’), 122.75 (C-5”), 121.06 (C-6, 6’), 117.98 (C-3”), 117.51 (b; C-4a, 4a’), 115.30 (C-8”), 115.20
(C-8, 8’), 114.88, 114.40 (C-m, 4a”), 105.56 (b; C-3, 3’), 60.88 (C-b), 55.40 (C-6b”), 36.10 (C-a),
30.19 ppm (b; C-1a, 1a’. EI-MS (m/z, %): 692 (M+, 18). Anal. Calcd for C40H32N6O6: C,
69.35; H, 4.66; N, 12.13. Found: C, 69.43; H, 4.51; N, 12.21.
4.2. Pharmacological Assays
4.2.1. Cytotoxic Activity Using MTT Assay and Evaluation of IC50
MTT Assay
An MTT assay was performed to investigate the effect of the synthesized com-
pounds on mammary epithelial cells (MCF-10A) at a concentration of 50 µM for the
tested compound. The cells were propagated in a medium consisting of Ham’s F-12
medium/Dulbecco’s modified Eagle’s medium (DMEM) (1:1) supplemented with 10%
fetal calf serum, 2 mM glutamine, insulin (10 µg/mL), hydrocortisone (500 ng/mL), and
epidermal growth factor (20 ng/mL). Trypsin ethylenediamine tetra acetic acid (EDTA)
was used to pass the cells every 2–3 days. Ninety-six-well flat-bottomed cell culture plates
were used to seed the cells at a density of 104 cells mL−1. The medium was aspirated from
all the wells of culture plates after 24 h followed by the addition of synthesized compounds
(in 200 µL medium to yield a final concentration of 0.1% (v/v) dimethylsulfoxide) into
individual wells of the plates. Four wells were designated to a single compound. The
plates were allowed to incubate at 37 ◦C for 96 h. Afterward, the medium was aspirated,
and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (0.4 mg/mL) in
the medium was added to each well and subsequently incubated for 3 h. The medium
was aspirated, and 150 µL dimethyl sulfoxide (DMSO) was added to each well. The plates
were vortexed, followed by the measurement of absorbance at 540 nm on a microplate
reader. The results were presented as inhibition (%) of proliferation compared to controls
comprising 0.1% DMSO.
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Assay for the Anti-Proliferative Effect
To explore the anti-proliferative potential of compounds, propidium iodide fluores-
cence assay was performed using different cell lines such as Panc-1 (pancreas cancer cell
line), MCF-7 (breast cancer cell line), HT-29 (colon cancer cell line), and A-549 (epithelial
cancer cell line), respectively. To calculate the total nuclear DNA, a fluorescent dye (propid-
ium iodide, PI) is used to attach to the DNA, thus offering a quick and precise technique.
PI cannot pass through the cell membrane, and its signal intensity can be considered as
directly proportional to the quantity of cellular DNA. Cells whose cell membranes are
damaged or have changed permeability are counted as dead ones. The assay was per-
formed by seeding the cells of different cell lines at a density of 3000–7500 cells/well (in
200 µL medium) in culture plates followed by incubation for 24 h at 37 ◦C in humidified
5%CO2/95% air atmospheric conditions. The medium was removed; the compounds were
added to the plates at 10 µM concentrations (in 0.1% DMSO) in triplicates, followed by
incubation for 48h. DMSO (0.1%) was used as a control. After incubation, the medium was
removed, followed by the addition of PI (25 µL, 50 µg/mL in water/medium) to each well
of the plates. At −80 ◦C, the plates were allowed to freeze for 24 h, followed by thawing at
25 ◦C. A fluorometer (Polar-Star BMG Tech, Beijing, China) was used to record the readings
at excitation and emission wavelengths of 530 and 620 nm for each well. The percentage





where ATC = absorbance of treated cells and AC = absorbance of control. Doxorubicin was
used as a positive control in the assay.
4.2.2. Caspase 3 Activation Assay
All reagents were allowed to reach room temperature before use. All liquid reagents
were gently mixed before use. The number of 8-well strips needed for the assay was
determined. These were inserted into the frame(s) for current use. A total of 100 µL of
the Standard Diluent Buffer was added to the zero standard wells. Well(s) reserved for
chromogen blank were left empty. A total of 100 µL of standards and controls or diluted
samples was added to the appropriate microtiter wells. The sample dilution chosen was
optimized for each experimental system. The side of the plate was gently tapped on to
mix. Wells were covered with a plate cover and incubated for 2 h at room temperature. The
solution was thoroughly aspirated or decanted from the wells and the liquid was discarded;
wells were washed four times. A total of 100 µL of Caspase 3 (Active) Detection Antibody
solution was pipetted into each well except the chromogen blank(s). The side of the plate
was gently tapped on to mix. The plate was covered with a plate cover and incubated for 1
h at room temperature. The solution was thoroughly aspirated or decanted from wells and
the liquid was discarded; wells were washed four times. A total of 100 µL Anti-Rabbit IgG
HRP Working Solution was added to each well except the chromogen blank(s).
The working dilution was prepared as described in Preparing IgG HRP. Wells were
covered with the plate cover and incubated for 30 min at room temperature. The solution
was thoroughly aspirated or decanted from the wells and the liquid was discarded. Wells
were washed four times. A total of 100 µL of Stabilized Chromogen was added to each well.
The liquid in the wells began to turn blue. It was incubated for 30 min at room temperature
and in the dark. The incubation time for chromogen substrate was determined by the
microtiter plate reader used.
Many plate readers have the capacity to record a maximum optical density (O.D.) of
2.0. The O.D. values were monitored, and the substrate reaction was stopped before the
O.D. of the positive wells exceeds the limits of the instrument. The O.D. values at 450 nm
could only be read after the Stop Solution had been added to each well. A total of 100 µL
of Stop Solution was added to each well. The side of the plate was gently tapped to mix.
The solution in the wells changed from blue to yellow. The absorbance of each well was
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read at 450 nm, having blanked the plate reader against a chromogen blank composed of
100 µL each of Stabilized Chromogen and Stop Solution. The plate was read within 2 h after
adding the Stop Solution. A curve fitting software was used to generate the standard curve.
A four-parameter algorithm provided the best standard curve fit. The concentrations for
unknown samples and controls from the standard curve were read. Value(s) obtained for
sample(s) by the appropriate dilution factor were multiplied to correct for the dilution in
step 3. Samples producing signals greater than that of the highest standard were diluted in
Standard Diluent Buffer and reanalyzed.
4.2.3. Caspase 8 Activation Assay
Cells were obtained from American Type Culture Collection; cells were grown in
RPMI 1640 containing 10% fetal bovine serum at 37 ◦C, stimulated with the compounds
to be tested for caspase8, and lysed with Cell Extraction Buffer. This lysate was diluted
in Standard Diluent Buffer over the range of the assay and measured for human active
Caspase 8 content. (cells were plated in a density of 1.2–1.8 × 10,000 cells/well in a volume
of 100 µL complete growth medium + 100 µL of the tested compound per well in a 96-well
plate for 24 h before the enzyme assay for Tubulin). The absorbance of each microwell
was read on a spectro-photometer at 450 nm. A standard curve was prepared from seven
human Caspase 8 standard dilutions, and human Caspase 8 concentration was determined.
4.2.4. Bax Activation Assay
All reagents, except the human Bax-α Standard, were brought to room temperature
for at least 30 min before opening. The human Bax-α Standard solution was not be left at
room temperature for more than 10 min. All standards, controls, and samples were run
in duplicate. The Assay Layout Sheet was used to determine the number of wells to be
used, and any remaining wells were put with the desiccant back into the pouch, and the
ziplock was sealed. Unused wells were stored at 4 ◦C. A total of 100 µL of Assay Buffer was
pipetted into the S0 (0 pg/mL standard) wells. A total of 100 µL of Standards #1 through
#6 was pipetted into the appropriate wells. A total of 100 µL of the samples was pipetted
into the appropriate wells. The plate was gently tapped to mix the contents. The plate
was sealed and incubated at room temperature on a plate shaker for 1 h at ~500 rpm. The
contents of the wells were emptied and washed by adding 400 µL of wash solution to every
well. The wash was repeated four more times for a total of five washes. After the final
wash, the wells were emptied or aspirated and firmly the plate on a lint-free paper towel
was tapped to remove any remaining wash buffer. A total of 100 µL of yellow antibody
was pipetted into each well, except the Blank. The plate was sealed and incubated at room
temperature on a plate shaker for 1 h at ~500 rpm. The contents of the wells were emptied
and washed by adding 400 µL of wash solution to every well. The wash was repeated
four more times for a total of five washes. After the final wash, the wells were emptied
or aspirated, and the plate was firmly tapped on a lint-free paper towel to remove any
remaining wash buffer. A total of 100 µL of blue Conjugate was added to each well, except
the Blank. The plate was sealed and incubated at room temperature on a plate shaker
for 30 min at ~500 rpm. The contents of the wells were emptied and washed by adding
400 µL of wash solution to every well. The wash was repeated four more times for a total
of five washes. After the final wash, the wells were emptied or aspirated and the plate
was firmly tapped on a lint-free paper towel to remove any remaining wash buffer. A total
of 100 µL of Substrate Solution was pipetted into each well. It was incubated for 30 min
at room temperature on a plate shaker at ~500 rpm. A total of 100 µL Stop Solution was
pipetted into to each well. The plate reader was blanked against the Blank wells, and
the optical density was read at 450 nm. The average net optical density (OD) bound for
each standard and sample was calculated by subtracting the average Blank OD from the
average OD for each standard and sample. Using linear graph paper, the Average Net OD
for each standard versus Bax concentration in each standard were plotted. A straight line
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was approximated through the points. The concentration of Bax in the unknowns could be
determined by interpolation.
4.2.5. Bcl-2 Inhibition Assay
All reagents were thoroughly mixed without foaming before use. The microwells
were washed twice with approximately 300 µL Wash Buffer per well with the thorough
aspiration of microwell contents between washes. Care was taken not to scratch the surface
of the microwells. After the last wash, the wells were emptied and microwell strips were
tapped on an absorbent pad or paper towel to remove excess Wash Buffer. The microwell
strips were used immediately after washing or placed upside down on a wet absorbent
paper for not longer than 15 min. Wells were not allowed to dry. A total of 100 µL of
Sample Diluent was added in duplicate to all standard wells and the blank wells. Standard
(1:2 dilution) in duplicate was prepared ranging from 32 to 0.5 ng/mL. A total of 100 µL
of Sample Diluent, in duplicate, was added to the blank wells. A total of 80 µL of Sample
Diluent, in duplicate, was added to the sample wells. A total of 20 µL of each sample,
in duplicate, was added to the designated wells. A total of 50 µL of diluted biotin was
added, conjugated to all wells, including the blank wells. It was covered with a plate cover
and incubated at room temperature on a microplate shaker at 100 rpm for 2 h. The plate
cover was removed and the wells were emptied. Microwell strips were washed times
as described in Step 2. A total of 100 µL of diluted Streptavidin-HRP was added to all
wells, including the blank wells. It was covered with a plate cover and incubated at room
temperature on a microplate shaker at 100 rpm for 1 h. The plate cover was removed
and the wells were emptied. Microwell strips were washed three times, as described in
Step 2. A total of 100 µL of mixed TMB Substrate Solution was pipetted into all wells,
including the blanks. The microwell strips were incubated at room temperature (18 ◦C
to 25 ◦C) for about 15 min, on a rotator set at 100 rpm. Direct exposure to intense light
was avoided. The point at which the substrate reaction is stopped was determined by
the ELISA reader. Many ELISA readers record absorbance only up to 2.0 O.D. Therefore,
the color development within individual microwells was watched by the person running
the assay, and the substrate reaction was stopped before positive wells were no longer
properly detectable. The enzyme reaction was stopped by quickly pipetting 100 µL of Stop
Solution into each well, including the blank wells. It was important that the Stop Solution
was spread quickly and uniformly throughout the microwells to inactivate the enzyme
completely. Results were read immediately after the Stop Solution was added or within
one hour if the microwell strips were stored at 2–8 ◦C in the dark. The absorbance of each
microwell was read on a spectrophotometer using 450 nm as the primary wavelength.
4.2.6. Cytochrome C Assay
Cells were obtained from American Type Culture Collection, grown in RPMI 1640
containing 10% fetal bovine serum at 37 ◦C, stimulated with the compounds to be tested for
cytochrome C, and lysed with Cell Extraction Buffer. This lysate was diluted in Standard
Diluent Buffer over the range of the assay and measured for cytochrome C content. (cells
were plated in cells/well in a volume of 100 µL complete growth medium + 100 µL of the
tested compound + 50 µL of 1× biotin-conjugated antibody + 100 µL of 1× streptavidin-
HRP + 100 µL TMB substrate soln of per well in a 96-well plate for 24 h before assay).
4.2.7. Cell Apoptosis Assay
Apoptosis was determined by flow cytometry based on the annexin V-fluorescein isothio-
cyanate (FITC) and propidium iodide (PI) staining kit (BD Pharmingen, San Diego, CA, USA).
Apoptotic cells were defined as Annexin-V-positive. Cells were grown to approximately
~70% confluency and exposed to the tested compounds (8 µmol/L) for 24 h. Treated cells
were trypsinized, washed twice with PBS, and transferred into microcentrifuge tubes for
centrifugation at 1000 rpm for 5 min at room temperature, and then resuspended in binding
buffer; 5 µL of FITC and PI were added to per Eppendorf tube, and cells were vortexed and
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incubated for 15 min at room temperature in the dark. Subsequently, cells were analyzed
by flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA).
Supplementary Materials: The following are available online, Spectral data of all newly synthesized
compounds.
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